Sign Out
Symtuza is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40 kg).
Genotypic testing should guide the use of Symtuza (see Dosage & Administration, Precautions, and Pharmacology: Pharmacodynamics under Actions).
Continue with Google